MedPath

Clinical study on safety assessment of PRP therapy for development dysplasia of hip(PRP for hip dysplasia)

Phase 1
Conditions
Patients who is diagnosed Hip osteoarthritis (Kellgren and Lawrence grade 4) due to development dysp
Registration Number
JPRN-jRCTb030190271
Lead Sponsor
Homma Yasuhiro
Brief Summary

According to the experience in one patient in this study and the evidences reported recently,it was considered that the PRP injection for patient of hip dysplasia with endstage osteoarthritis was not scientifically validated. Thereby,this resarech was cancelled.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
1
Inclusion Criteria

1.Patients who have symptoms for more than 3 months
2.Patients who have continued pain even after taking NSAIDs for 6 week or more and who can not use NSAIDs for asthma and digestive tract ulcer
3. More than 20 years old
4. Other , patients who the doctor has determined that it is suitable for this clinical study

Exclusion Criteria

1.Patients with a history of hip surgery
2. Patients with abnormal platelet counts in peripheral blood
3.Person who smokes a lot (Brinkmanindex>600)
4. Treatment with anticoagulants(Warfarin)
5. Uncontrolled diabetes mellitus : HbA1c not lower than 9.0% according to latest laboratory data obtained within 14 days before registration
6. Patients with malignancy
7. Patients less than 6 months after onset of cardiac infarction or cerebral infarction
8. Predictive survival period is less
than 1 year
9. Active infectious disease (HBV, HCV, HTLV-1, HIV, syphilis)
10.Dialysis patients
11. Compromised host
12.Requiring continued use of oral corticosteroid therapy
13. Less than 20 years old
14.Doctor has determined that it is not suitable for this clinical study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath